Thomson Reuters Launches $500M Buyback Amid AI-Driven Stock Decline

What happened

Thomson Reuters announced plans to repurchase up to $500 million of its shares under a new normal course issuer bid approved by the Toronto Stock Exchange. This follows the completion of a previous $1.0 billion repurchase program in October 2025 and comes amid a roughly 47% stock price decline over the past year, with shares now trading around $88.53. Management clearly views the shares as undervalued relative to its FY2026 guidance for 7.5%–8.0% organic revenue growth and approximately 100 basis points of EBITDA margin expansion, and has the free cash flow (guided to ~$2.1 billion) to fund both AI investments and capital returns without adding leverage. The announcement signals continued confidence in the company's ability to navigate AI-driven competitive threats and convert its GenAI product cadence into durable paid attach, which remains the central bull thesis. However, investors should note that buybacks alone do not resolve the core uncertainty around pricing power erosion and the pace of GenAI monetization, which will require evidence from upcoming quarterly prints and ACV mix data.

Implication

The new $500 million repurchase program, combined with the existing dividend (10% increase to $2.62 per share), demonstrates that management sees current valuation as attractive and is willing to deploy excess cash to support the stock. Given TRI's low leverage (0.4x net debt/EBITDA) and strong free cash flow generation (~$2.1B guided for FY2026), the buyback is unlikely to impair the company's ability to fund the >$200 million annual organic AI investment in Legal or pursue strategic M&A. However, the announcement should not overshadow the central investment debate: whether TRI can sustain pricing power in the face of agentic AI competition and translate its 28% GenAI-enabled ACV mix into higher renewal uplift and seat expansion. The buyback may provide a floor to the stock, but the path to a rerating still hinges on delivering the Q1 2026 checkpoint of ~7% organic growth and ~42% EBITDA margin, and on showing that 'Deep Research' launches in H1 2026 convert to paid upgrades. Investors should treat capital return announcements as a sign of discipline, but continue to monitor the leading indicators of AI monetization and competitive discounting for any deterioration that would undermine the thesis.

Thesis delta

The announcement of a new $500 million buyback program reinforces the existing view that TRI's strong free cash flow and low leverage provide a margin of safety, as management can return capital while maintaining AI investments. It modestly increases confidence in near-term downside protection but does not alter the central thesis that the stock's rerating depends on evidence that GenAI features (CoCounsel, Deep Research) are converting to paid attach without triggering competitive discounting. If anything, aggressive buybacks at current prices suggest management believes the market is overestimating AI-driven erosion, but investors should still base decisions on observable operating metrics rather than capital return signals alone.